Browse by category

SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events

Headline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a...

Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG

4 days ago

Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss

5 days ago

Racial and ethnic groups face barriers to obtaining OMMs

5 days ago

Weekly Digest